Palvella to Present Three Posters on Microcystic Lymphatic Malformations and DSAP
Palvella Therapeutics will present three posters with new data on microcystic lymphatic malformations and DSAP at Fall Clinical Dermatology 2026.
Topic
Drug Pipeline
Topic
Drug Pipeline
Pemphigus Vulgaris Therapy Pipeline Expands Beyond Rituximab
A new EMJ review details how pemphigus vulgaris treatment is broadening beyond rituximab, with pipeline candidates targeting fast…
Alumis Reports Phase III Wins for Oral Psoriasis Pill, Analysts Unmoved
Alumis posted a set of Phase III wins for its oral psoriasis pill, yet analysts remain lukewarm on the program's commercial impac…
Dermatology Times Publishes Clinician FAQ on Hair Loss Pipeline
Dermatology Times has published a clinician-focused FAQ on the hair-loss treatment pipeline, organizing investigational-therapy i…
Tulisokibart Posts Efficacy in Phase 2b for Moderate-to-Severe HS
Tulisokibart demonstrated efficacy in a Phase 2b study of patients with moderate to severe hidradenitis suppurativa, HCPLive repo…
UCB's Galvokimig Advances in Atopic Dermatitis Pipeline
UCB's atopic dermatitis candidate galvokimig cleared transcriptomic and biomarker analyses, per The Dermatology Digest's AD Pipel…
Pfizer Eczema Drug Posts 61% Response as Florida Sues
Pfizer's eczema drug posted a 61% response rate the same day Florida sued the company, creating a split narrative of clinical pro…
Pfizer Reports Tilrekimig Phase 2 Atopic Dermatitis Results
Pfizer has disclosed Phase 2 atopic dermatitis results for tilrekimig, its mid-stage candidate; detailed efficacy and safety data…
Pfizer Reports Significant Skin Clearance with Eczema Drug
Pfizer says its eczema drug shows significant skin clearance in patients, a claim that puts the candidate in the competitive atop…
Nektar Presents Biomarker Data on Atopic Dermatitis Candidate
Nektar Therapeutics has presented biomarker data on its investigational atopic dermatitis drug, offering early pharmacologic insi…